Trade leaders from the U.S. cosmetics and private care sector gathered on Capitol Hill final month to reconnect with lawmakers and reinforce key coverage priorities. Organized by the Private Care Merchandise Council (PCPC), the “Again-to-Session” reception introduced collectively greater than a dozen corporations to highlight the sector’s regulatory, financial, and scientific agenda as Congress returned from recess.
The occasion, held on September 10, centered on the reauthorization of the Over-the-Counter Monograph Consumer Charge Act (OMUFA), implementation of MoCRA, enlargement of non-animal testing strategies, tariff aid, and the necessity for regulatory consistency.
We spoke to Karin Ross, govt vp of presidency affairs at PCPC for deeper insights into the occasion’s discussions and the group’s positioning on present legislative points.
OTC drug reform and FDA sunscreen evaluations beneath the microscope
As Congress seems forward to the following spherical of OTC drug consumer price negotiations, PCPC is urging lawmakers to maintain provisions within the OMUFA reauthorization that may modernize the FDA’s sunscreen evaluation course of and open the door to newer testing strategies.
“The language is predicated on the SAFE Sunscreen Requirements Act and focuses on increasing non-animal testing strategies that the FDA can undertake when reviewing new energetic elements,” Ross informed CosmeticsDesign. “We proceed to advocate for non-animal testing strategies and trendy UV filter approval processes for sunscreen security evaluations, and this language will assist modernize the regulatory framework.”
MoCRA guidelines take form as corporations prep for deadlines
With key rulemakings anticipated in late 2025 and early 2026, PCPC members are conserving a detailed watch on how the FDA will roll out remaining necessities beneath MoCRA. Readability on timing, scope, and enforcement stays a prime concern.
“Our members are intently watching the upcoming perfume allergen and Good Manufacturing Practices rule and proceed to prioritize clear, well timed steering from the FDA to make sure possible compliance throughout companies of all sizes,” Ross stated. “We’ve labored to supply our members with the instruments and assets essential to navigate compliance.”
She added that many corporations have already accomplished preliminary necessities like facility registration and product itemizing. Whereas no main technical fixes are on the desk, Ross stated PCPC is “monitoring to make sure the regulatory framework stays clear and workable.”
Momentum builds round non-animal testing laws
Non-animal testing continues to be a excessive precedence for the business, with rising assist on Capitol Hill for laws that may formalize its use and develop federal acceptance of latest security evaluation instruments.
“Our member corporations have performed a number one function in advancing various security evaluation strategies,” Ross stated. “As regulators and lawmakers take into account learn how to additional implement non-animal testing strategies, evidentiary requirements needs to be science-based, internationally harmonized the place potential, and versatile sufficient to evolve as new strategies are validated.”
She pointed to the Humane Cosmetics Act and OMUFA reauthorization as two instant alternatives to maneuver the problem ahead. “If handed, the HCA would align U.S. rules with these of different international locations which have adopted animal check bans or regulatory frameworks that emphasize using non-animal testing strategies.”
Tariff aid efforts goal important inputs, not shortcuts
Provide chain pressures stay a priority for a lot of magnificence producers, significantly with regards to tariffs on specialised elements and packaging not available within the U.S. PCPC is asking lawmakers to zero in on narrowly focused aid to guard jobs and protect home operations.
“We’re at the moment participating with policymakers on this matter to make sure U.S. producers stay aggressive, proceed producing within the U.S., and shield the roles and innovation our business helps,” Ross stated.
PCPC can be pushing for extra recognition of the U.S.-Mexico-Canada Settlement (USMCA) as a mannequin for future commerce offers. “Extra importantly, USMCA is the one U.S. commerce settlement that establishes commitments on good regulatory practices for cosmetics —together with the Beauty Annex, which has delivered significant advantages to our business.”
In 2024, cross-border cosmetics commerce in North America surpassed $10 billion. “U.S. exports to Canada and Mexico, valued at practically $6 billion, now surpass mixed exports to China and Europe,” Ross stated.
State-level bans complicate MoCRA’s unified framework
As states proceed to introduce ingredient bans and new labeling guidelines, corporations are elevating considerations {that a} patchwork of conflicting insurance policies might undermine federal regulation and disrupt compliance efforts.
“Based mostly on the newest information, we assist 4.6 million jobs, generate $308.7 billion in GDP, and contribute $82.3 billion in tax income,” Ross stated. “With manufacturing operations in practically each state, our business generated $68 billion in U.S. output in 2022 and has constantly delivered a commerce surplus for practically three many years.”
She emphasised that MoCRA was meant to be a unified, science-based framework. “Nevertheless, state-level ingredient bans, and different regulatory necessities typically create an advanced patchwork of conflicting guidelines that undermine federal regulation,” Ross stated. “That’s the reason we emphasize the significance of MoCRA and the vital function of the FDA.”
